HC Andersen Capital: FDA approval of NeoNavia Q&A session with NeoDynamics, CEO Anna Eriksrud, and CFO Aaron Wong

HC Andersen Capital hosted a Q&A session with the management from NeoDynamics, CEO Anna Eriksrud, and CFO Aaron Wong. NeoDynamics recently received FDA approval for the promising NeoNavia™ pulse biopsy system in the US.

Get a short update on the NeoNavia system, targeting the biopsy market with focus on breast cancer and how NeoDynamics will approach the US market. The company already has a strong management/organization in place in the US and is ready to launch the product with full commercialization in 2023. The CEO Anna Eriksrud updates you on why they got the approval so fast, and CFO Aaron Wong dives into the market growth and earlier published target for the total addressable market in 2025 of USD 830 Mio.

The company is fully financed to carry out earlier announced plans. They include further penetration of the European market and commercialization of the US market. Finally, management updates you on the progression in the European market. Wednesday 21st of September NeoDynamics released news regarding a partnership with Decomplix in the Swiss market. New requirements from May 2022 in Switzerland, require foreign manufacturers that place medical devices on the Swiss market to appoint a Swiss Authorized Representative.

Watch the video here: https://www.youtube.com/watch?v=hjedcap2e_U.

This is a press release from HC ANDERSEN CAPITAL https://hcandersencapital.dk.

Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a Digital IR / Corporate Visibility subscription agreement.

HC ANDERSEN CAPITAL
Claus Thestrup, CEO Sweden
claus@hcandersencapital.dk